Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

BUY
$47.98 - $54.4 $4,510 - $5,113
94 Added 2.11%
4,554 $246,000
Q4 2023

Feb 01, 2024

BUY
$48.48 - $57.85 $145 - $173
3 Added 0.07%
4,460 $228,000
Q3 2023

Oct 13, 2023

SELL
$57.89 - $64.73 $27.5 Million - $30.8 Million
-475,562 Reduced 99.07%
4,457 $258,000
Q2 2023

Jul 17, 2023

SELL
$63.71 - $70.74 $4.48 Million - $4.97 Million
-70,327 Reduced 12.78%
480,019 $30.7 Million
Q1 2023

Apr 11, 2023

BUY
$65.71 - $74.53 $3.45 Million - $3.91 Million
52,452 Added 10.53%
550,346 $38.1 Million
Q4 2022

Jan 17, 2023

SELL
$68.48 - $81.09 $905,648 - $1.07 Million
-13,225 Reduced 2.59%
497,894 $35.8 Million
Q3 2022

Oct 13, 2022

BUY
$0.13 - $76.84 $3,314 - $1.96 Million
25,493 Added 5.25%
511,119 $36.3 Million
Q2 2022

Jul 11, 2022

SELL
$72.62 - $79.98 $1.65 Million - $1.82 Million
-22,707 Reduced 4.47%
485,626 $37.4 Million
Q1 2022

Apr 12, 2022

SELL
$61.48 - $73.72 $2.48 Million - $2.98 Million
-40,401 Reduced 7.36%
508,333 $37.1 Million
Q4 2021

Jan 24, 2022

BUY
$53.63 - $62.52 $2.01 Million - $2.35 Million
37,550 Added 7.35%
548,734 $34.2 Million
Q3 2021

Oct 14, 2021

BUY
$59.17 - $69.31 $30 Million - $35.1 Million
506,767 Added 11473.1%
511,184 $30.2 Million
Q2 2021

Jul 14, 2021

SELL
$61.91 - $67.42 $62,962 - $68,566
-1,017 Reduced 18.72%
4,417 $295,000
Q1 2021

Apr 12, 2021

BUY
$59.34 - $66.74 $322,453 - $362,665
5,434 New
5,434 $343,000
Q1 2020

Apr 13, 2020

SELL
$46.4 - $67.43 $250,745 - $364,391
-5,404 Closed
0 $0
Q4 2019

Jan 15, 2020

BUY
$49.21 - $64.19 $65,547 - $85,501
1,332 Added 32.71%
5,404 $347,000
Q3 2019

Nov 01, 2019

BUY
$42.77 - $50.71 $174,159 - $206,491
4,072 New
4,072 $206,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $115B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Wedge Capital Management L L P Portfolio

Follow Wedge Capital Management L L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wedge Capital Management L L P, based on Form 13F filings with the SEC.

News

Stay updated on Wedge Capital Management L L P with notifications on news.